🚀 VC round data is live in beta, check it out!
Granules India Valuation Multiples
Discover revenue and EBITDA valuation multiples for Granules India and similar public comparables like Harmony Biosciences, Vir Biotechnology, Tsumura, Celltrion Pharm and more.
Granules India Overview
About Granules India
Granules India Ltd is an India-based pharmaceutical company. The company manufactures active pharmaceutical ingredients, pharmaceutical formulation intermediates, and finished dosages. It has one segment Pharmaceutical products including ingredients and intermediaries. Its primary geographic markets are North America, Latin America, Europe, India, and the Rest of the World. The company generates a majority of its revenue from its business outside India.
Founded
1991
HQ
Employees
4.1K
Website
Financials (LTM)
EV
$2B
Granules India Financials
Granules India reported last 12-month revenue of $574M and EBITDA of $125M.
In the same LTM period, Granules India generated $381M in gross profit, $125M in EBITDA, and $63M in net income.
Revenue (LTM)
Granules India P&L
In the most recent fiscal year, Granules India reported revenue of $525M and EBITDA of $111M.
Granules India expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $574M | XXX | $525M | XXX | XXX | XXX |
| Gross Profit | $381M | XXX | $282M | XXX | XXX | XXX |
| Gross Margin | 66% | XXX | 54% | XXX | XXX | XXX |
| EBITDA | $125M | XXX | $111M | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 21% | XXX | XXX | XXX |
| EBIT Margin | 16% | XXX | 16% | XXX | XXX | XXX |
| Net Profit | $63M | XXX | $58M | XXX | XXX | XXX |
| Net Margin | 11% | XXX | 11% | XXX | XXX | XXX |
| Net Debt | — | — | $88M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Granules India Stock Performance
Granules India has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Granules India's stock price is $7.03.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 0.9% | XXX | XXX | XXX | $0.23 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGranules India Valuation Multiples
Granules India trades at 3.3x EV/Revenue multiple, and 15.0x EV/EBITDA.
EV / Revenue (LTM)
Granules India Financial Valuation Multiples
As of April 18, 2026, Granules India has market cap of $2B and EV of $2B.
Equity research analysts estimate Granules India's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Granules India has a P/E ratio of 27.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 3.3x | XXX | 3.6x | XXX | XXX | XXX |
| EV/EBITDA | 15.0x | XXX | 16.9x | XXX | XXX | XXX |
| EV/EBIT | 19.9x | XXX | 22.2x | XXX | XXX | XXX |
| EV/Gross Profit | 4.9x | XXX | 6.6x | XXX | XXX | XXX |
| P/E | 27.5x | XXX | 30.1x | XXX | XXX | XXX |
| EV/FCF | (199.7x) | XXX | 59.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Granules India Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Granules India Margins & Growth Rates
Granules India's revenue in the last 12 month grew by 15%.
Granules India's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Granules India's rule of 40 is 39% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Granules India's rule of X is 63% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Granules India Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Growth | 21% | XXX | 12% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 39% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 63% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 6% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 39% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Granules India Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Contract Research & Manufacturing comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Granules India | XXX | XXX | XXX | XXX | XXX | XXX |
| Harmony Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Vir Biotechnology | XXX | XXX | XXX | XXX | XXX | XXX |
| Tsumura | XXX | XXX | XXX | XXX | XXX | XXX |
| Celltrion Pharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Hualan Biological Vaccine | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Granules India M&A Activity
Granules India acquired XXX companies to date.
Last acquisition by Granules India was on XXXXXXXX, XXXXX. Granules India acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Granules India
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGranules India Investment Activity
Granules India invested in XXX companies to date.
Granules India made its latest investment on XXXXXXXX, XXXXX. Granules India invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Granules India
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Granules India
| When was Granules India founded? | Granules India was founded in 1991. |
| Where is Granules India headquartered? | Granules India is headquartered in India. |
| How many employees does Granules India have? | As of today, Granules India has over 4K employees. |
| Who is the CEO of Granules India? | Granules India's CEO is Kandiraju Venkata Sitaram Rao. |
| Is Granules India publicly listed? | Yes, Granules India is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Granules India? | Granules India trades under GRANULES ticker. |
| When did Granules India go public? | Granules India went public in 2005. |
| Who are competitors of Granules India? | Granules India main competitors are Harmony Biosciences, Vir Biotechnology, Tsumura, Celltrion Pharm. |
| What is the current market cap of Granules India? | Granules India's current market cap is $2B. |
| What is the current revenue of Granules India? | Granules India's last 12 months revenue is $574M. |
| What is the current revenue growth of Granules India? | Granules India revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of Granules India? | Current revenue multiple of Granules India is 3.3x. |
| Is Granules India profitable? | Yes, Granules India is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Granules India? | Granules India's last 12 months EBITDA is $125M. |
| What is Granules India's EBITDA margin? | Granules India's last 12 months EBITDA margin is 22%. |
| What is the current EV/EBITDA multiple of Granules India? | Current EBITDA multiple of Granules India is 15.0x. |
| What is the current FCF of Granules India? | Granules India's last 12 months FCF is ($9M). |
| What is Granules India's FCF margin? | Granules India's last 12 months FCF margin is (2%). |
| What is the current EV/FCF multiple of Granules India? | Current FCF multiple of Granules India is (199.7x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.